Cara Therapeutic

NASDAQ: CARA
$4.60
-$0.05 (-1.1%)
Closing Price on January 21, 2025

CARA Stock Chart and Intraday Price

CARA Stock Data

Asset Type Common Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 4 STAMFORD PLAZA, 107 ELM STREET 9TH FLOOR, STAMFORD, CT, US
Fiscal Year End December
Latest Quarter 2023-12-31
Market Cap 45.14M USD
Shares Outstanding 54,656,000
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on itching and pain by selectively targeting kappa opioid receptors in the United States. The company is headquartered in Stamford, Connecticut.

CARA Articles

Thursday's Top Analyst Downgrades and Upgrades: Costco, CrowdStrike, Dick's Sporting Goods, GE, PayPal, Six Flags and More
Thursday's top analyst upgrades and downgrades included AGNC Investment, Costco Wholesale, CrowdStrike, Dick’s Sporting Goods, Fifth Third Bancorp, General Electric, PayPal, Sabre, Six Flags...
Lee Jackson
Published:

Tuesday Afternoon's Top Analyst Upgrades and Downgrades: Biogen, BP, Caterpillar, Riot Blockchain, Squarespace and More
Tuesday afternoon's top analyst upgrades and downgrades included Biogen, BP, Caterpillar, Riot Blockchain, Squarespace and more.
Chris Lange
Published:

Why Mixed Results From This Chronic Kidney Disease Study Aren't That Great
Cara Therapeutics shares were crushed on Tuesday after the firm announced results from its midstage trial in patients with chronic kidney disease.
Chris Lange
Published:
Last Updated:
AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.